ALLIED CORP - ALID STOCK NEWS

Allied Corp (OTCQB: ALID) has announced a significant milestone, surpassing 120 full-time employees at its wholly owned subsidiary, Allied Colombia SAS. This growth reflects the company's expansion in production capacity, as Allied prepares for the international export of cannabis flower from Colombia. CEO Calum Hughes highlighted the importance of a strong team to ensure consistent, quality output. Allied is positioned as a leader in the medical cannabis sector, with plans to enhance its product offerings and explore potential US market expansion.

Allied Corp (OTCQB: ALID) has appointed Mr. Jay McMillan as Chief Commercial Officer for its Consumer Packaged Goods division. In this role, he will focus on national sales and distribution while overseeing the manufacturing supply chain. With 25 years of international experience, McMillan previously helped HEXO Corp become a top licensed producer. His expertise aligns with Allied’s retail brands: Tactical Relief, Equilibrium Bio, and MaXXa. The company continues to pursue growth in the expanding cannabis market, preparing for potential U.S. legalization while focusing on product development.

Allied Corp (OTCQB: ALID) announced a supply contract with Veterans For Healing (VFH) for 2022, focusing on the export of high-CBD cannabis flower. The contract specifies a monthly supply of 4,000 kilograms, split between the U.S. and U.K. markets. This partnership aims to produce high-CBD cigarette packages branded with VFH, featuring the Allied Inside™ mark. The Allied Inside™ model allows partners to import large volumes of cannabis while minimizing upfront costs. CEO Calum Hughes emphasized the contract highlights global demand for cannabis and the company's readiness to supply international markets.

Allied Corp (OTCQB: ALID) announced a contract with a Mexican partner to distribute its retail-ready products in Mexico, effective November 18, 2021. These products, manufactured in the US and compliant with the 0.3% THC threshold, will be sold in pharmacies and health retail locations across Mexico. The agreement is structured as a rolling monthly supply contract, with expectations for volume increases as Allied aims to capture a growing market share. The CEO highlighted the positive market response, particularly in relation to their Tactical Relief™, Equilibrium Bio™, and MaXXa™ product lines.

Allied Corp (OTCQB: ALID) announced advancements in its Psilonex™ RX human clinical phase I trial targeting depression, anxiety, and PTSD. The company has successfully sourced the active pharmaceutical ingredients for Psilonex™ and is transitioning to production at selected clinical research sites. Psilonex™ RX combines psilocybin and other medicinal ingredients, with a market potential of approximately US$30.4 billion across the three conditions. Allied's strategic focus aims to integrate research with commercial viability in the pharmaceutical domain.

Allied Corp announces the launch of its wholesale cannabis product line called Allied Inside™. The trademark for this brand was filed on October 30, 2021. The Allied Inside™ approach aims to standardize quality and consistency in cannabis products, produced in Colombia to European Pharmacopeia standards. This model allows international partners to avoid production costs and risks while offering competitive pricing. With several contracts signed for 2022, Allied highlights its readiness to supply as soon as regulations permit.

Allied Corp (OTCQB: ALID) has announced a significant supply agreement for 2022, involving the delivery of 12,000 kilograms of dried cannabis flower to a U.S. Multi-State Operator starting January 2022. The company will only sell cannabis flower in legal markets, adhering to the Colombian government's regulations. Additionally, Allied secured a purchase order for branded CBD products to be sold in California and Nevada, complying with the 2018 Farm Bill THC limits of 0.3%. CEO Calum Hughes emphasized their capacity to deliver fresh supply regularly.

Allied Corp (OTCQB: ALID) has signed multiple supply contracts for cannabis flower for the 2022 calendar year. The first contract, effective September 30, 2021, covers 85,000 kilograms, followed by 40,000 kilograms on September 27, and 24,000 kilograms on September 28, with various partners experienced in pharmaceutical and agricultural sectors. These contracts position Allied to leverage growing global cannabis demand, particularly as Colombia prepares for potential exports. CEO Calum Hughes emphasizes the importance of these contracts in meeting international market needs.

Allied Corp (OTCQB: ALID) has received additional licensing in Colombia, enabling the company to operate as a research and plant breeding unit for both psychoactive and non-psychoactive cannabis. This licensing allows for the import/export of cannabis seeds, independent research, and agronomic evaluations of their cannabis strains. CEO Calum Hughes expressed excitement about developing custom cannabinoid profiles and the potential for international market showcase, as Colombia advances towards cannabis flower exportation.